{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T21:13:42Z","timestamp":1790975622091,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01393-1","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:18:16Z","timestamp":1777022296000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advances in Pharmacologic- and Non-pharmacologic Interventions for Cancer Pain: A Narrative Review"],"prefix":"10.1007","volume":"27","author":[{"given":"Shulin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"1","key":"1393_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/j.pain.0000000000001363","volume":"160","author":"MI Bennett","year":"2019","unstructured":"Bennett MI, Kaasa S, Barke A, et al. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain. 2019;160(1):38\u201344. https:\/\/doi.org\/10.1097\/j.pain.0000000000001363.","journal-title":"Pain"},{"issue":"1","key":"1393_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s43556-025-00289-0","volume":"6","author":"WL Wang","year":"2025","unstructured":"Wang WL, Hao YH, Pang X, Tang YL. Cancer pain: molecular mechanisms and management. Mol Biomed. 2025;6(1):45. https:\/\/doi.org\/10.1186\/s43556-025-00289-0.","journal-title":"Mol Biomed"},{"issue":"5","key":"1393_CR3","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/j.jpainsymman.2021.12.021","volume":"63","author":"A Ruano","year":"2022","unstructured":"Ruano A, Garc\u00eda-Torres F, G\u00e1lvez-Lara M, Moriana JA. Psychological and Non-Pharmacologic Treatments for Pain in Cancer Patients: A Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2022;63(5):e505\u201320. https:\/\/doi.org\/10.1016\/j.jpainsymman.2021.12.021.","journal-title":"J Pain Symptom Manage"},{"key":"1393_CR4","doi-asserted-by":"publisher","unstructured":"Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ. Update on Prevalence of Pain in Patients with Cancer 2022: A Systematic Literature Review and Meta-Analysis. Cancers (Basel). 2023;15(3). https:\/\/doi.org\/10.3390\/cancers15030591.","DOI":"10.3390\/cancers15030591"},{"key":"1393_CR5","unstructured":"Anekar AA, Hendrix JM, Cascella M. WHO Analgesic Ladder. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC. 2025."},{"issue":"19","key":"1393_CR6","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1200\/jco.24.00542","volume":"42","author":"JJ Sanders","year":"2024","unstructured":"Sanders JJ, Temin S, Ghoshal A, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol. 2024;42(19):2336\u201357. https:\/\/doi.org\/10.1200\/jco.24.00542.","journal-title":"J Clin Oncol"},{"key":"1393_CR7","doi-asserted-by":"publisher","unstructured":"Swarm RA, Youngwerth JM, Agne JL, et al. Adult Cancer Pain, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(7). https:\/\/doi.org\/10.6004\/jnccn.2025.0032.","DOI":"10.6004\/jnccn.2025.0032"},{"issue":"10","key":"1393_CR8","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s11864-023-01115-x","volume":"24","author":"T Geyer","year":"2023","unstructured":"Geyer T, Le NS, Groissenberger I, Jutz F, Tschurlovich L, Kreye G. Systemic Anticancer Treatment Near the End of Life: a Narrative Literature Review. Curr Treat Options Oncol. 2023;24(10):1328\u201350. https:\/\/doi.org\/10.1007\/s11864-023-01115-x.","journal-title":"Curr Treat Options Oncol"},{"key":"1393_CR9","doi-asserted-by":"publisher","first-page":"914591","DOI":"10.3389\/fonc.2022.914591","volume":"12","author":"X Wu","year":"2022","unstructured":"Wu X, Qin F, Zhang Q, et al. Immunotherapy improved cancer related pain management in patients with advanced Hepato-Pancreatic Biliary Cancers: A propensity score-matched (PSM) analysis. Front Oncol. 2022;12:914591. https:\/\/doi.org\/10.3389\/fonc.2022.914591.","journal-title":"Front Oncol"},{"issue":"5","key":"1393_CR10","doi-asserted-by":"publisher","first-page":"105082","DOI":"10.1016\/j.esmoop.2025.105082","volume":"10","author":"X Hu","year":"2025","unstructured":"Hu X, Curigliano G, Yonemori K, et al. Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial. ESMO Open. 2025;10(5):105082. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105082.","journal-title":"ESMO Open"},{"issue":"10","key":"1393_CR11","doi-asserted-by":"publisher","first-page":"e1324","DOI":"10.1093\/oncolo\/oyae087","volume":"29","author":"W Mansoor","year":"2024","unstructured":"Mansoor W, Joo S, Norquist JM, et al. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer. Oncologist. 2024;29(10):e1324\u201335. https:\/\/doi.org\/10.1093\/oncolo\/oyae087.","journal-title":"Oncologist"},{"issue":"10","key":"1393_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1093\/jnci\/djz101","volume":"111","author":"KL Spencer","year":"2019","unstructured":"Spencer KL, van der Velden JM, Wong E, et al. Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases. J Natl Cancer Inst. 2019;111(10):1023\u201332. https:\/\/doi.org\/10.1093\/jnci\/djz101.","journal-title":"J Natl Cancer Inst"},{"key":"1393_CR13","doi-asserted-by":"publisher","first-page":"1161752","DOI":"10.3389\/fonc.2023.1161752","volume":"13","author":"A Iannalfi","year":"2023","unstructured":"Iannalfi A, Riva G, Ciccone L, Orlandi E. The role of particle radiotherapy in the treatment of skull base tumors. Front Oncol. 2023;13:1161752. https:\/\/doi.org\/10.3389\/fonc.2023.1161752.","journal-title":"Front Oncol"},{"key":"1393_CR14","doi-asserted-by":"publisher","first-page":"1421067","DOI":"10.3389\/fonc.2024.1421067","volume":"14","author":"Y Sun","year":"2024","unstructured":"Sun Y, Jiang W, Liao X, Wang D. Hallmarks of perineural invasion in pancreatic ductal adenocarcinoma: new biological dimensions. Front Oncol. 2024;14:1421067. https:\/\/doi.org\/10.3389\/fonc.2024.1421067.","journal-title":"Front Oncol"},{"issue":"4","key":"1393_CR15","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","volume":"110","author":"KR Crews","year":"2021","unstructured":"Crews KR, Monte AA, Huddart R, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888\u201396. https:\/\/doi.org\/10.1002\/cpt.2149.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1393_CR16","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00520-019-04828-8","volume":"27","author":"B George","year":"2019","unstructured":"George B, Minello C, Allano G, et al. Opioids in cancer-related pain: current situation and outlook. Support Care Cancer. 2019;27(8):3105\u201318. https:\/\/doi.org\/10.1007\/s00520-019-04828-8.","journal-title":"Support Care Cancer"},{"issue":"5","key":"1393_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/s1470-2045(09)70350-x","volume":"11","author":"S Mercadante","year":"2010","unstructured":"Mercadante S. Intravenous morphine for management of cancer pain. Lancet Oncol. 2010;11(5):484\u20139. https:\/\/doi.org\/10.1016\/s1470-2045(09)70350-x.","journal-title":"Lancet Oncol"},{"key":"1393_CR18","doi-asserted-by":"publisher","unstructured":"Formenti P, Umbrello M, Pignataro M, et al. Managing Severe Cancer Pain with Oxycodone\/Naloxone Treatment: A Literature Review Update. J Pers Med. 2024;14(5). https:\/\/doi.org\/10.3390\/jpm14050483.","DOI":"10.3390\/jpm14050483"},{"issue":"Supplement","key":"1393_CR19","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.4103\/0973-1482.171368","volume":"14","author":"DD Wang","year":"2018","unstructured":"Wang DD, Ma TT, Zhu HD, Peng CB. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials. J Cancer Res Ther. 2018;14(Supplement):S14\u201321. https:\/\/doi.org\/10.4103\/0973-1482.171368.","journal-title":"J Cancer Res Ther"},{"issue":"2","key":"1393_CR20","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1124\/jpet.123.001651","volume":"387","author":"S Coates","year":"2023","unstructured":"Coates S, Lazarus P, Hydrocodone. Oxycodone, and Morphine Metabolism and Drug-Drug Interactions. J Pharmacol Exp Ther. 2023;387(2):150\u201369. https:\/\/doi.org\/10.1124\/jpet.123.001651.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1393_CR21","doi-asserted-by":"publisher","first-page":"Cd011108","DOI":"10.1002\/14651858.CD011108.pub2","volume":"10","author":"YJ Bao","year":"2016","unstructured":"Bao YJ, Hou W, Kong XY, et al. Hydromorphone for cancer pain. Cochrane Database Syst Rev. 2016;10(10):Cd011108. https:\/\/doi.org\/10.1002\/14651858.CD011108.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"1393_CR22","doi-asserted-by":"publisher","first-page":"e683","DOI":"10.1016\/j.jpainsymman.2023.01.013","volume":"65","author":"A Reddy","year":"2023","unstructured":"Reddy A, Haider A, Arthur J, et al. Levorphanol as a Second Line Opioid in Cancer Patients Presenting to an Outpatient Supportive Care Center: An Open-label Study. J Pain Symptom Manage. 2023;65(6):e683\u201390. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.01.013.","journal-title":"J Pain Symptom Manage"},{"key":"1393_CR23","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2147\/jpr.S322893","volume":"14","author":"MZ Liu","year":"2021","unstructured":"Liu MZ, Ma J, Li JD, et al. A Comparison of the Clinical Effectiveness Between Low-Dose Strong Opioids and Non-Steroidal Anti-Inflammatory Drugs in the Treatment of Mild Cancer Pain: A Randomized Trial. J Pain Res. 2021;14:3411\u20139. https:\/\/doi.org\/10.2147\/jpr.S322893.","journal-title":"J Pain Res"},{"issue":"3","key":"1393_CR24","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jpainsymman.2023.05.002","volume":"66","author":"O Leiva-V\u00e1squez","year":"2023","unstructured":"Leiva-V\u00e1squez O, Letelier LM, Rojas L, et al. Is Acetaminophen Beneficial in Patients With Cancer Pain Who are on Strong Opioids? A Randomized Controlled Trial. J Pain Symptom Manage. 2023;66(3):183\u2013e921. https:\/\/doi.org\/10.1016\/j.jpainsymman.2023.05.002.","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"1393_CR25","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1177\/02692163221122263","volume":"36","author":"AJ Page","year":"2022","unstructured":"Page AJ, Spencer K, Mulvey MR, Laird BJ, Bennett MI. Non-steroidal anti-inflammatory drugs (NSAIDs) in cancer pain: A database analysis to determine recruitment feasibility for a clinical trial. Palliat Med. 2022;36(9):1440\u20135. https:\/\/doi.org\/10.1177\/02692163221122263.","journal-title":"Palliat Med"},{"issue":"4","key":"1393_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","volume":"69","author":"CC Szeto","year":"2020","unstructured":"Szeto CC, Sugano K, Wang JG, APAGE\/APLAR\/APSDE, et al. Gut. 2020;69(4):617\u201329. https:\/\/doi.org\/10.1136\/gutjnl-2019-319300. \/APSH\/APSN\/PoA recommendations.","journal-title":"Gut"},{"key":"1393_CR27","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","volume":"357","author":"M Bally","year":"2017","unstructured":"Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909. https:\/\/doi.org\/10.1136\/bmj.j1909.","journal-title":"BMJ"},{"issue":"2","key":"1393_CR28","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1097\/pr9.0000000000000995","volume":"7","author":"G Sohi","year":"2022","unstructured":"Sohi G, Lao N, Caraceni A, et al. Nonopioid drug combinations for cancer pain: a systematic review. Pain Rep. 2022;7(2):e995. https:\/\/doi.org\/10.1097\/pr9.0000000000000995.","journal-title":"Pain Rep"},{"issue":"2","key":"1393_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.21037\/tcr-20-2692","volume":"10","author":"H Bao","year":"2021","unstructured":"Bao H, Wu Z, Wang Q, et al. The efficacy of gabapentin combined with opioids for neuropathic cancer pain: a meta-analysis. Transl Cancer Res. 2021;10(2):637\u201344. https:\/\/doi.org\/10.21037\/tcr-20-2692.","journal-title":"Transl Cancer Res"},{"issue":"1","key":"1393_CR30","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1186\/s12885-021-09069-9","volume":"21","author":"M Sugimoto","year":"2021","unstructured":"Sugimoto M, Takagi T, Suzuki R, et al. Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients. BMC Cancer. 2021;21(1):1319. https:\/\/doi.org\/10.1186\/s12885-021-09069-9.","journal-title":"BMC Cancer"},{"issue":"9","key":"1393_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s11864-024-01248-7","volume":"25","author":"MR Mulvey","year":"2024","unstructured":"Mulvey MR, Paley CA, Schuberth A, et al. Neuropathic Pain in Cancer: What Are the Current Guidelines? Curr Treat Options Oncol. 2024;25(9):1193\u2013202. https:\/\/doi.org\/10.1007\/s11864-024-01248-7.","journal-title":"Curr Treat Options Oncol"},{"issue":"28","key":"1393_CR32","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","volume":"38","author":"CL Loprinzi","year":"2020","unstructured":"Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325\u201348. https:\/\/doi.org\/10.1200\/JCO.20.01399.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1393_CR33","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.annonc.2020.07.003","volume":"31","author":"B Jordan","year":"2020","unstructured":"Jordan B, Margulies A, Cardoso F, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306\u201319. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.003.","journal-title":"Ann Oncol"},{"issue":"1","key":"1393_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1177\/1049909116683720","volume":"35","author":"P White","year":"2018","unstructured":"White P, Arnold R, Bull J, Cicero B. The Use of Corticosteroids as Adjuvant Therapy for Painful Bone Metastases: A Large Cross-Sectional Survey of Palliative Care Providers. Am J Hosp Palliat Care. 2018;35(1):151\u20138. https:\/\/doi.org\/10.1177\/1049909116683720.","journal-title":"Am J Hosp Palliat Care"},{"issue":"4","key":"1393_CR35","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1089\/jpm.2019.0243","volume":"23","author":"Y Qian","year":"2020","unstructured":"Qian Y, Haider A, Lu Z, et al. Factors Associated with Improvement in Uncontrolled Cancer Pain without Increasing the Opioid Daily Dose among Patients Seen by an Inpatient Palliative Care Team. J Palliat Med. 2020;23(4):483\u20138. https:\/\/doi.org\/10.1089\/jpm.2019.0243.","journal-title":"J Palliat Med"},{"issue":"34","key":"1393_CR36","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/jco.22.01357","volume":"40","author":"JJ Mao","year":"2022","unstructured":"Mao JJ, Ismaila N, Bao T, et al. Integrative Medicine for Pain Management in Oncology: Society for Integrative Oncology-ASCO Guideline. J Clin Oncol. 2022;40(34):3998\u20134024. https:\/\/doi.org\/10.1200\/jco.22.01357.","journal-title":"J Clin Oncol"},{"key":"1393_CR37","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/cmar.S404934","volume":"15","author":"N Li","year":"2023","unstructured":"Li N, Cui M, Wang Y. Effect of Dexmedetomidine for Palliative Sedation for Refractory Dyspnoea in Patients with Terminal-Stage Cancer. Cancer Manag Res. 2023;15:291\u20139. https:\/\/doi.org\/10.2147\/cmar.S404934.","journal-title":"Cancer Manag Res"},{"key":"1393_CR38","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2147\/jpr.S191543","volume":"12","author":"HG Kress","year":"2019","unstructured":"Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019;12:1553\u201360. https:\/\/doi.org\/10.2147\/jpr.S191543.","journal-title":"J Pain Res"},{"issue":"6","key":"1393_CR39","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00540-020-02821-8","volume":"34","author":"S Sazuka","year":"2020","unstructured":"Sazuka S, Koitabashi T. Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-na\u00efve and opioid-tolerant patients: a retrospective study. J Anesth. 2020;34(6):834\u201340. https:\/\/doi.org\/10.1007\/s00540-020-02821-8.","journal-title":"J Anesth"},{"issue":"4","key":"1393_CR40","doi-asserted-by":"publisher","first-page":"B12","DOI":"10.5055\/bupe.24.rpj.1075","volume":"20","author":"M Silveira","year":"2024","unstructured":"Silveira M, Powell V. Buprenorphine for Cancer Pain: Results from a Systematic Review. J Opioid Manag. 2024;20(4):B12. https:\/\/doi.org\/10.5055\/bupe.24.rpj.1075.","journal-title":"J Opioid Manag"},{"issue":"10","key":"1393_CR41","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1089\/jpm.2018.0533","volume":"22","author":"KA Donovan","year":"2019","unstructured":"Donovan KA, Chang YD, Oberoi-Jassal R, et al. Relationship of Cannabis Use to Patient-Reported Symptoms in Cancer Patients Seeking Supportive\/Palliative Care. J Palliat Med. 2019;22(10):1191\u20135. https:\/\/doi.org\/10.1089\/jpm.2018.0533.","journal-title":"J Palliat Med"},{"issue":"1","key":"1393_CR42","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11912-019-0757-7","volume":"21","author":"G Steele","year":"2019","unstructured":"Steele G, Arneson T, Zylla D. A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety. Curr Oncol Rep. 2019;21(1):10. https:\/\/doi.org\/10.1007\/s11912-019-0757-7.","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"1393_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00520-025-09763-5","volume":"33","author":"JR Hardy","year":"2025","unstructured":"Hardy JR, Greer RM, Pelecanos AM, et al. Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol. Support Care Cancer. 2025;33(8):715. https:\/\/doi.org\/10.1007\/s00520-025-09763-5.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1393_CR44","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1186\/s12885-023-11560-4","volume":"23","author":"S Misawa","year":"2023","unstructured":"Misawa S, Denda T, Kodama S, et al. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study). BMC Cancer. 2023;23(1):1098. https:\/\/doi.org\/10.1186\/s12885-023-11560-4.","journal-title":"BMC Cancer"},{"issue":"12","key":"1393_CR45","doi-asserted-by":"publisher","first-page":"e1268","DOI":"10.1093\/oncolo\/oyad188","volume":"28","author":"M Fallon","year":"2023","unstructured":"Fallon M, Sopata M, Dragon E, et al. A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis. Oncologist. 2023;28(12):e1268\u201378. https:\/\/doi.org\/10.1093\/oncolo\/oyad188.","journal-title":"Oncologist"},{"issue":"6","key":"1393_CR46","doi-asserted-by":"publisher","first-page":"EVIDoa2400423","DOI":"10.1056\/EVIDoa2400423","volume":"4","author":"AJ Mannes","year":"2025","unstructured":"Mannes AJ, Heiss JD, Berger A, et al. Treatment of Intractable Cancer Pain with Resiniferatoxin - An Interim Study. NEJM Evid. 2025;4(6):EVIDoa2400423. https:\/\/doi.org\/10.1056\/EVIDoa2400423.","journal-title":"NEJM Evid"},{"key":"1393_CR47","doi-asserted-by":"publisher","unstructured":"Bienfait F, Julienne A, Jubier-Hamon S, et al. Evaluation of 8% Capsaicin Patches in Chemotherapy-Induced Peripheral Neuropathy: A Retrospective Study in a Comprehensive Cancer Center. Cancers (Basel). 2023;15(2). https:\/\/doi.org\/10.3390\/cancers15020349.","DOI":"10.3390\/cancers15020349"},{"issue":"7","key":"1393_CR48","doi-asserted-by":"publisher","first-page":"6838","DOI":"10.3390\/curroncol30070500","volume":"30","author":"F Mestdagh","year":"2023","unstructured":"Mestdagh F, Steyaert A, Lavand\u2019homme P. Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques. Curr Oncol. 2023;30(7):6838\u201358. https:\/\/doi.org\/10.3390\/curroncol30070500.","journal-title":"Curr Oncol"},{"issue":"3","key":"1393_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jpainsymman.2025.05.015","volume":"70","author":"JT Lee","year":"2025","unstructured":"Lee JT, Lovell MR, Ritchie M, et al. Lidocaine for Neuropathic Cancer Pain (LiCPain): A Pilot Randomized Controlled Trial. J Pain Symptom Manage. 2025;70(3):267\u2013e776. https:\/\/doi.org\/10.1016\/j.jpainsymman.2025.05.015.","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"1393_CR50","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.14309\/ctg.0000000000000760","volume":"15","author":"S Augustinus","year":"2024","unstructured":"Augustinus S, Bieze M, Van Veldhuisen CL, et al. Intravenous Lidocaine for Refractory Pain in Patients With Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Multicenter Prospective Nonrandomized Pilot Study. Clin Transl Gastroenterol. 2024;15(9):e1. https:\/\/doi.org\/10.14309\/ctg.0000000000000760.","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"1393_CR51","first-page":"203","volume":"23","author":"A Rocha","year":"2020","unstructured":"Rocha A, Plancarte R, Nataren RGR, et al. Effectiveness of Superior Hypogastric Plexus Neurolysis for Pelvic Cancer Pain. Pain Physician. 2020;23(2):203\u20138.","journal-title":"Pain Physician"},{"issue":"4","key":"1393_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.36076\/ppj\/2019.19.281","volume":"19","author":"D Koyyalagunta","year":"2016","unstructured":"Koyyalagunta D, Engle MP, Yu J, Feng L, Novy DM. The Effectiveness of Alcohol Versus Phenol Based Splanchnic Nerve Neurolysis for the Treatment of Intra-Abdominal Cancer Pain. Pain Physician. 2016;19(4):281\u201392.","journal-title":"Pain Physician"},{"issue":"10","key":"1393_CR53","doi-asserted-by":"publisher","first-page":"e30944","DOI":"10.7759\/cureus.30944","volume":"14","author":"A Paul","year":"2022","unstructured":"Paul A, Borkar A. Fluoroscopy-Guided Splanchnic Nerve Block for Cancer-Associated Pain. Cureus. 2022;14(10):e30944. https:\/\/doi.org\/10.7759\/cureus.30944.","journal-title":"Cureus"},{"issue":"7","key":"1393_CR54","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.neurom.2024.08.006","volume":"28","author":"TR Deer","year":"2025","unstructured":"Deer TR, Hayek SM, Grider JS, et al. The Polyanalgesic Consensus Conference (PACC)\u00ae: Updates on Clinical Pharmacology and Comorbidity Management in Intrathecal Drug Delivery for Cancer Pain. Neuromodulation. 2025;28(7):1029\u201353. https:\/\/doi.org\/10.1016\/j.neurom.2024.08.006.","journal-title":"Neuromodulation"},{"issue":"14","key":"1393_CR55","doi-asserted-by":"publisher","first-page":"e34522","DOI":"10.1016\/j.heliyon.2024.e34522","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Shi Q, Cao Y, Fan B, Yang Y. Intrathecal drug delivery systems for cancer pain: A retrospective analysis at a single tertiary medical center in China. Heliyon. 2024;10(14):e34522. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e34522.","journal-title":"Heliyon"},{"issue":"2","key":"1393_CR56","first-page":"1","volume":"24","author":"Intrathecal Drug Delivery Systems for Cancer Pain","year":"2024","unstructured":"Intrathecal Drug Delivery Systems for Cancer Pain. A Health Technology Assessment. Ont Health Technol Assess Ser. 2024;24(2):1\u2013162.","journal-title":"Ont Health Technol Assess Ser"},{"key":"1393_CR57","doi-asserted-by":"publisher","unstructured":"Paolini F, Ferini G, Bonosi L, et al. Spinal Cord Stimulation to Treat Unresponsive Cancer Pain: A Possible Solution in Palliative Oncological Therapy. Life (Basel). 2022;12(4). https:\/\/doi.org\/10.3390\/life12040554.","DOI":"10.3390\/life12040554"},{"key":"1393_CR58","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.2147\/jpr.S263857","volume":"13","author":"JM Hagedorn","year":"2020","unstructured":"Hagedorn JM, Pittelkow TP, Hunt CL, D\u2019Souza RS, Lamer TJ. Current Perspectives on Spinal Cord Stimulation for the Treatment of Cancer Pain. J Pain Res. 2020;13:3295\u2013305. https:\/\/doi.org\/10.2147\/jpr.S263857.","journal-title":"J Pain Res"},{"issue":"5","key":"1393_CR59","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.neurom.2022.01.023","volume":"25","author":"JE Crowther","year":"2022","unstructured":"Crowther JE, Chen GH, Legler A, Gulati A. Spinal Cord Stimulation in the Treatment of Cancer Pain: A Retrospective Review. Neuromodulation. 2022;25(5):693\u20139. https:\/\/doi.org\/10.1016\/j.neurom.2022.01.023.","journal-title":"Neuromodulation"},{"issue":"11","key":"1393_CR60","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/nmd.0000000000001713","volume":"211","author":"A Mansouri","year":"2023","unstructured":"Mansouri A, Javedani M, Rezazadeh Yazd SA, et al. The Efficacy of Cognitive-Behavioral Group Therapy on Depression, Anxiety, and Pain-Coping Strategies in Women With Breast Cancer. J Nerv Ment Dis. 2023;211(11):835\u201340. https:\/\/doi.org\/10.1097\/nmd.0000000000001713.","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"1393_CR61","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/07347332.2022.2046676","volume":"41","author":"HM Fisher","year":"2023","unstructured":"Fisher HM, Stalls J, Winger JG, et al. Role of self-efficacy for pain management and pain catastrophizing in the relationship between pain severity and depressive symptoms in women with breast cancer and pain. J Psychosoc Oncol. 2023;41(1):87\u2013103. https:\/\/doi.org\/10.1080\/07347332.2022.2046676.","journal-title":"J Psychosoc Oncol"},{"issue":"12","key":"1393_CR62","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/pon.4883","volume":"27","author":"K Kwekkeboom","year":"2018","unstructured":"Kwekkeboom K, Zhang Y, Campbell T, et al. Randomized controlled trial of a brief cognitive-behavioral strategies intervention for the pain, fatigue, and sleep disturbance symptom cluster in advanced cancer. Psychooncology. 2018;27(12):2761\u20139. https:\/\/doi.org\/10.1002\/pon.4883.","journal-title":"Psychooncology"},{"key":"1393_CR63","doi-asserted-by":"publisher","unstructured":"Han Q, Wang H, Wang K, et al. Global landscape and hotspot analysis of meditation research in cancer: a bibliometric study. J Cancer Surviv. 2025. https:\/\/doi.org\/10.1007\/s11764-025-01784-7.","DOI":"10.1007\/s11764-025-01784-7"},{"issue":"11","key":"1393_CR64","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/scan\/nsz104","volume":"14","author":"H Kober","year":"2019","unstructured":"KoberH, Buhle J, Weber J, Ochsner KN, Wager TD. Let it be: mindful acceptance down-regulates pain and negative emotion. Soc Cogn Affect Neurosci. 2019;14(11):1147\u201358. https:\/\/doi.org\/10.1093\/scan\/nsz104.","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"2","key":"1393_CR65","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10880-022-09862-z","volume":"29","author":"LY Lin","year":"2022","unstructured":"Lin LY, Lin LH, Tzeng GL, et al. Effects of Mindfulness-Based Therapy for Cancer Patients: A Systematic Review and Meta-analysis. J Clin Psychol Med Settings. 2022;29(2):432\u201345. https:\/\/doi.org\/10.1007\/s10880-022-09862-z.","journal-title":"J Clin Psychol Med Settings"},{"issue":"1","key":"1393_CR66","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12888-025-06599-5","volume":"25","author":"A Getie","year":"2025","unstructured":"Getie A, Ayalneh M, Bimerew M. Global prevalence and determinant factors of pain, depression, and anxiety among cancer patients: an umbrella review of systematic reviews and meta-analyses. BMC Psychiatry. 2025;25(1):156. https:\/\/doi.org\/10.1186\/s12888-025-06599-5.","journal-title":"BMC Psychiatry"},{"issue":"5","key":"1393_CR67","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jpainsymman.2025.07.030","volume":"70","author":"EJ Shim","year":"2025","unstructured":"Shim EJ, Ha H, Yeom CW, et al. Depression and Cancer Pain: Mediating Roles of Anxiety and Pain Beliefs. J Pain Symptom Manage. 2025;70(5):481\u20139. https:\/\/doi.org\/10.1016\/j.jpainsymman.2025.07.030.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"1393_CR68","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1634\/theoncologist.2019-0470","volume":"25","author":"M van der Vorst","year":"2020","unstructured":"van der Vorst M, Neefjes ECW, Boddaert MSA, et al. Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. Oncologist. 2020;25(3):e570\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0470.","journal-title":"Oncologist"},{"issue":"4","key":"1393_CR69","doi-asserted-by":"publisher","first-page":"276","DOI":"10.48095\/ccko2022276","volume":"35","author":"Z \u0160oukalov\u00e1","year":"2022","unstructured":"\u0160oukalov\u00e1 Z. Olanzapine in oncology palliative care. Klin Onkol. 2022;35(4):276\u201383. https:\/\/doi.org\/10.48095\/ccko2022276.","journal-title":"Klin Onkol"},{"issue":"3","key":"1393_CR70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00520-024-08352-2","volume":"32","author":"K Kurisu","year":"2024","unstructured":"Kurisu K, Inada S, Maeda I, et al. Effectiveness of antipsychotics for managing agitated delirium in patients with advanced cancer: a secondary analysis of a multicenter prospective observational study in Japan (Phase-R). Support Care Cancer. 2024;32(3):147. https:\/\/doi.org\/10.1007\/s00520-024-08352-2.","journal-title":"Support Care Cancer"},{"issue":"1","key":"1393_CR71","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13020-021-00558-4","volume":"17","author":"L Ge","year":"2022","unstructured":"Ge L, Wang Q, He Y, et al. Acupuncture for cancer pain: an evidence-based clinical practice guideline. Chin Med. 2022;17(1):8. https:\/\/doi.org\/10.1186\/s13020-021-00558-4.","journal-title":"Chin Med"},{"issue":"22","key":"1393_CR72","doi-asserted-by":"publisher","first-page":"e70170","DOI":"10.1002\/cncr.70170","volume":"131","author":"M Yang","year":"2025","unstructured":"Yang M, Zhong L, Fok RWY, et al. Effects and safety of traditional Chinese medicine approaches in cancer symptom care: A systematic review of phase 3 randomized clinical trials. Cancer. 2025;131(22):e70170. https:\/\/doi.org\/10.1002\/cncr.70170.","journal-title":"Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01393-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01393-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:18:19Z","timestamp":1777022299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01393-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1393"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01393-1","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The figure and table included in our manuscript are original and were created by the authors. They are not reproduced or adapted from any previously published materials, and no permissions are required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permissions"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}